Eli Lilly is pairing up with a so-called “dark genome” biotech startup to hunt for a new generation of obesity and metabolic drugs.
The Indianapolis …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.